Tcheng, J. E., Lincoff, A. M., Miller, D. P., Booth, J. E., Rund, M. M., Cabot, C. F., … Topol, E. J. (1997). Benefits of abciximab accrue in the full spectrum of coronary interventional patients: Insights from the EPILOG trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 29(2), 9931–9931.

Tcheng, J. E., A. M. Lincoff, D. P. Miller, J. E. Booth, M. M. Rund, C. F. Cabot, H. F. Weisman, R. M. Califf, and E. J. Topol. “Benefits of abciximab accrue in the full spectrum of coronary interventional patients: Insights from the EPILOG trial.” JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 29, no. 2 (February 1, 1997): 9931–9931.

Tcheng JE, Lincoff AM, Miller DP, Booth JE, Rund MM, Cabot CF, et al. Benefits of abciximab accrue in the full spectrum of coronary interventional patients: Insights from the EPILOG trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 1997 Feb 1;29(2):9931–9931.

Tcheng, J. E., et al. “Benefits of abciximab accrue in the full spectrum of coronary interventional patients: Insights from the EPILOG trial.” JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 29, no. 2, ELSEVIER SCIENCE INC, Feb. 1997, pp. 9931–9931.

Tcheng JE, Lincoff AM, Miller DP, Booth JE, Rund MM, Cabot CF, Weisman HF, Califf RM, Topol EJ. Benefits of abciximab accrue in the full spectrum of coronary interventional patients: Insights from the EPILOG trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC; 1997 Feb 1;29(2):9931–9931.